0503.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 lapkr. 2023 @ 10:08):

Stats
Šios dienos apimtis	13.96M
Vidutinė apimtis	476 561
Rinkos kapitalizacija	750.60M
EPS	HKD0 ( 2023-08-24 )
Last Dividend	HKD1.497 ( 2021-09-13 )
Next Dividend	HKD0 ( N/A )
P/E	13.77
ATR14	HKD0.0150 (0.84%)

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: 0.00 (neutral)

Signal:(54.908) Neutral

Lansen Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Lansen Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.27
( neutral )

0.38
( neutral )

0.00
( neutral )

-0.05
( neutral )

-0.11
( neutral )

0.18
( neutral )

Lansen Pharmaceutical Finansinės ataskaitos

Annual	2022
Pajamos:	HKD65.56M
Bruto pelnas:	HKD44.30M (67.57 %)
EPS:	HKD0.0205

FY	2022
Pajamos:	HKD65.56M
Bruto pelnas:	HKD44.30M (67.57 %)
EPS:	HKD0.0205

FY	2021
Pajamos:	HKD54.18M
Bruto pelnas:	HKD34.41M (63.51 %)
EPS:	HKD0.00224

FY	2020
Pajamos:	HKD54.39M
Bruto pelnas:	HKD35.18M (64.68 %)
EPS:	HKD0.218

Financial Reports:

No articles found.

Lansen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Lansen Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.21 - good (82.09%) | Divividend Growth Potential Score: 2.16 - No dividend growth expected in the near future

Information

First Dividend	HKD0.0136	2011-04-20
Last Dividend	HKD1.497	2021-09-13
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	19	--
Total Paid Out	HKD2.55	--
Avg. Dividend % Per Year	0.00%	--
Score	2.25	--
Div. Sustainability Score	8.21
Div.Growth Potential Score	2.16
Div. Directional Score	5.19	--

Next Divdend (Est)
(2024-07-15)

HKD0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

2.25

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2883.HK	Ex Dividend Knight	2023-06-07	Annually	0.00%
1480.HK	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
0551.HK	Ex Dividend Junior	2023-09-12	Annually	0.00%
8053.HK	No Dividend Player	2023-09-28	Annually	0.00%
2001.HK	Ex Dividend Knight	2023-09-01	Annually	0.00%
1072.HK	Ex Dividend Junior	2023-06-30	Sporadic	0.00%
0151.HK	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
3669.HK	Ex Dividend Junior	2023-09-07	Annually	0.00%
1635.HK	Ex Dividend Junior	2023-06-30	Annually	0.00%
0686.HK	Ex Dividend Junior	2023-06-29	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.114	1.500	7.72	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0424	1.200	8.59	10.00	[0 - 0.3]
returnOnEquityTTM	0.0604	1.500	-0.440	-0.661	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.54	0.800	2.28	1.820	[1 - 3]
quickRatioTTM	1.500	0.800	5.88	4.71	[0.8 - 2.5]
cashRatioTTM	0.939	1.500	5.89	8.84	[0.2 - 2]
debtRatioTTM	0.101	-1.500	8.31	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.00596	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.00460	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.144	-1.500	9.43	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.660	1.000	2.33	2.33	[0.2 - 0.8]
operatingProfitMarginTTM	0.191	1.000	8.18	8.18	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.142	1.000	-0.323	-0.323	[0.2 - 2]
assetTurnoverTTM	0.371	0.800	-0.859	-0.687	[0.5 - 2]
Total Score				8.21

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.03	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.0604	2.50	-0.283	-0.661	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.00460	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.00596	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00938	1.500	-3.27	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0388	1.000	-1.530	0	[0.1 - 0.5]
Total Score				2.16

Lansen Pharmaceutical

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People's Republic of China and internationally. The company operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. It offers Chinese medicine generic drugs; cosmetic products; and healthcare products. The company was founded in 2001 and is headquartered in Ningbo, the People's Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.